In 2019, Mesoblast Ltd (MSB) plans to work diligently with the U.S. Food and Drug Administration (FDA) to submit a rolling Biologics License Application for use of remestemcel-L in treating acute graft versus host disease (aGVHD) in children, and will execute on the product candidate’s market access and commercialization strategyhttp://crweworld.com/article/news-provided-by-globenewswire/930707/mesoblast-highlights-2019-key-priorities-for-its-leading-cellular-medicines-pipeline-at-biotech-showcase-in-san-francisco
- Forums
- ASX - By Stock
- MSB
- Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase
MSB
mesoblast limited
Add to My Watchlist
0.00%
!
$1.62

Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.62 |
Change
0.000(0.00%) |
Mkt cap ! $2.063B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5 | $1.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.52 | 685 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5 | 1.715 |
1 | 1006 | 1.685 |
1 | 768 | 1.650 |
1 | 519 | 1.645 |
3 | 8511 | 1.620 |
Price($) | Vol. | No. |
---|---|---|
1.515 | 685 | 2 |
1.535 | 12905 | 1 |
1.580 | 3500 | 2 |
1.615 | 5000 | 1 |
1.620 | 36001 | 4 |
Last trade - 09.48am 08/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
AGC
AUSTRALIAN GOLD AND COPPER LTD
Glen Diemar, MD
Glen Diemar
MD
SPONSORED BY The Market Online